Has two different single-isomer versions of fluoxetine (Eli Lilly's Prozac) in preclinicals for depression and migraine indications. Speaking Nov. 19 at the Robertson Stephens medical conference, Sepracor President Timothy Barberich said that the company's R-fluoxetine, which has a much shorter half-life than the racemic version, may not exhibit the side effects exhibited by regular fluoxetine when used to treat migraine. In the Nov. 25 issue of "The Pink Sheet," it was reported that Barberich made this claim about the Sepracor's S-fluoxetine for depression.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth